Labetuzumab-SN-38: Phase I started

Immunomedics disclosed in its fiscal year 2011 earnings ending June 30 that it began an open-label, dose-escalation Phase I trial evaluating IV labetuzumab-SN-38 every 2 weeks in about 24 patients. ...